Trojan Bio logo — Harnessing viral specific immunity for fighting cancer

Trojan Bio

Harnessing viral specific immunity for fighting cancer

Founded 2021 Israel Israel 8 employees Pre-Seed AI, Manufacturing +1

General Information

Company Name Trojan Bio
Founded Year 2021
Location Israel Israel
Employees 8
Industries AI, Manufacturing, Pharmaceutical
Funding Stage Pre-Seed
Social

BounceWatch is an independent company data service, not affiliated with Trojan Bio. To contact Trojan Bio, visit trojan-bio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Trojan Bio compare?

A PDF of Trojan Bio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Trojan Bio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Trojan Bio

Trojan Bio is an Israeli startup founded in 2021, specializing in harnessing viral specific immunity for fighting cancer. The company's slogan, "Harnessing viral specific immunity for fighting cancer," encapsulates its mission to develop a novel class of therapeutic antibodies for treating various cancers. Trojan Bio's unique approach involves integrating viral peptides into their antibodies to efficiently activate the immune system for cancer eradication. The company operates in the industries of AI, Manufacturing, and Pharmaceutical. Trojan Bio recently secured a Pre Seed Round investment on 01 January 2022 from the venture capital firm NFX. This investment will likely fuel the further development and advancement of Trojan Bio's groundbreaking cancer treatment technology.

Business keywords: immunotherapy, cancer treatment, therapeutic antibodies, viral peptides, immune system activation, pre-clinical research, cancer eradication, oncology, viral-specific immunity

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Pre Seed Round Undisclosed 1
NFX
01 Jan 2022

Trojan Bio Alternatives & Competitors

Trojan Bio vs

Immunotherapy against cancer. 4 clinical-stage products. 2 novel platforms: Invir.IO™ and myvac®

Post-IPO Equity
213 employees
Biotechnology, Manufacturing
Trojan Bio vs

Biolojic Design is a biopharmaceutical company dedicated to the development of human antibody-based...

70 employees
AI, Biotechnology
Trojan Bio vs

biosyn Arzneimittel GmbH is a pharmaceutical company promoting immune health in Germany's Pharmaland

30 employees
Biotechnology, Manufacturing

FAQ About Trojan Bio

Harnessing viral specific immunity for fighting cancer
Trojan Bio was founded in 2021.
Trojan Bio is headquartered in Israel.
Trojan Bio operates in AI, Manufacturing and Pharmaceutical. Its work centres on immunotherapy, cancer treatment, therapeutic antibodies and viral peptides.
Trojan Bio has approximately 8 employees.
Trojan Bio has completed 1 funding round. The latest funding stage is Pre-Seed.
Top alternatives and competitors to Trojan Bio include Transgene, Biolojic Design, Ltd., biosyn Arzneimittel GmbH, BioInvent International AB, NorthStar Medical Radioisotopes, LLC. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Trojan Bio and Transgene are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Trojan Bio, https://bouncewatch.com/company/trojan-bio, updated 26 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes